DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/djkgl4/therapeutic_class) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide, Astellas/Medivation), Zytiga (Abiraterone acetate, JNJ), Jevtana (Cabazitaxel, Sanofi), & Xofigo (radium Ra 223, Boehringer Ingelheim) has evolved the treatment paradigm of treating late stage prostate cancer. In coming years, the authors expect this to repeat in early stage prostate cancer treatment (nmCRPC, before Prostectomy) due to launch of newer antiandrogens in this setting. Longer duration of therapy and high prevalence makes this earlier setting market more lucrative and bigger for newer options than late stage if they succeed.

In coming years, the authors expect second generation antiandrogens (Androgen synthesis inhibitors/Androgen receptor inhibitors, Xtandi, ARN-509, ODM-021, Zytiga, TAK-700, TOK-001) to replace them and expand their use beyond current levels in nmCRPC (non metastatic Castrate resistance Prostate cancer) patients and also in pre-prostectomy (Chart 3). This newer agents will expand these markets at least by $10b ($6b in pre prostectomy, $4b nmCRPC) if get success.

TAK-700 (Takeda), ARN-509 (JNJ) and Xtandi are strong candidates to get success in early stage prostate cancer and in next two years PhIII clinical data from EL-04, PROSPER and SPARTAN study, will decide who will lead this market.

Key Topics Covered:

Executive Summary

Future role of Oral Antiandrogens in treatment of Prostate Cancer

Oral Anti-androgens use in earlier setting

Xtandi in neoadjuvant setting

Xtandi vs. Zytiga- Do Zytiga patent expiry is a Major threat for Xtandi???

Androgen Receptor inhibitors: Who could be the major threat to Xtandi?

Ongoing Clinical trials of ARN-509 and our expectations

ARN-509- Clinical data comparison vs. Xtandi and other pipeline candidates

Androgen Synthesis inhibitors: Do the pipeline candidates have potential to replace Zytiga?

Indirect near term key competitors to Zytiga/Xtandi in Post chemo setting:

For more information visit http://www.researchandmarkets.com/research/djkgl4/therapeutic_class

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets